# Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

> **NCT01296243** · PHASE2 · UNKNOWN · sponsor: **Genta Incorporated** · enrollment: 57 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Tesetaxel

## Key facts

- **NCT ID:** NCT01296243
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-02
- **Primary completion:** 2012-08
- **Final completion:** 2015-02
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2012-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01296243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01296243, "Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01296243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*